The Anti-Parkinsonian A2A Receptor Antagonist Istradefylline (KW-6002) Attenuates Behavioral Abnormalities, Neuroinflammation, and Neurodegeneration in Cerebral Ischemia: An Adenosinergic Signaling Link Between Stroke and Parkinson's Disease.
- Published in:
- International Journal of Molecular Sciences, 2025, v. 26, n. 12, p. 5680, doi. 10.3390/ijms26125680
- By:
- Publication type:
- Article